congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
T-DXd
ASCPT 2024 Annual Meeting | March 27-29, 2024
Exposure-response of trastuzumab deruxtecan (T-DXd) in subjects with HER2-low metastatic breast cancer
Poster
T-DXd
ASCPT 2024 Annual Meeting | March 27-29, 2024
Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-low metastatic breast cancer